doripenem has been researched along with Cystic Fibrosis of Pancreas in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Dargahi, Z; Etemad, A; Ghasemian, E; Hashemian, M; Kaviar, VH; Lohrasbi, A; Saadh, MJ | 1 |
| Abdalhamid, B; Fowler, RC; Hanson, ND; Harrison, LB; Selmecki, A | 1 |
| Kemper, AL; Young, DC; Zobell, JT | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Maitte, A; Potel, G | 1 |
| Elborn, JS; Parkins, MD | 1 |
| Bergen, PJ; Bulitta, JB; Forrest, A; Jacob, J; Li, J; Nation, RL; Paterson, DL; Sidjabat, HE; Tsuji, BT | 1 |
| Black, PL; Cirillo, I; Kearns, GL; Redman, R; Vaccaro, N | 1 |
| Chen, Y; Garber, E; Ge, Y; Kaniga, K; Saiman, L; Wikler, MA; Zhao, Q | 1 |
| Brown, SD; Traczewski, MM | 1 |
2 review(s) available for doripenem and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cystic Fibrosis; Doripenem; Humans; Minocycline; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus aureus; Stenotrophomonas maltophilia; Tigecycline | 2010 |
1 trial(s) available for doripenem and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Young Adult | 2012 |
6 other study(ies) available for doripenem and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
lptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Cell Membrane; Codon, Nonsense; Cystic Fibrosis; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Humans; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Mutation, Missense; Permeability; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Whole Genome Sequencing | 2019 |
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Colony Count, Microbial; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Half-Life; Humans; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Burkholderia cepacia; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2006 |